Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001104659-15-060960.pdf
0001104659-15-060960.rtf
0001104659-15-060960.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-15-060957.pdf
0001104659-15-060957.rtf
0001104659-15-060957.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-15-058308.pdf
0001104659-15-058308.rtf
0001104659-15-058308.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-15-001584.pdf
0001558370-15-001584.rtf
0001558370-15-001584.xls
EX-101.INS - EX-101.INS
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001104659-15-049338.pdf
0001104659-15-049338.rtf
0001104659-15-049338.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-15-048626.pdf
0001104659-15-048626.rtf
0001104659-15-048626.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000315066-15-002739.pdf
0000315066-15-002739.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-15-045941.pdf
0001104659-15-045941.rtf
0001104659-15-045941.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-15-001077.pdf
0001558370-15-001077.rtf
0001558370-15-001077.xls
EX-101.INS - EX-101.INS
4

Statement of changes in beneficial ownership of securities

 View HTML
0001012975-15-000330.pdf
0001012975-15-000330.rtf
0001012975-15-000330.xls